Changes and clinical significance of ischemia modified albumin, high-sensitivity C-reactive protein and CXC ligand 16 in early acute coronary syndrome patients
GU Zhi-miao1, YANG Zhen-yu2
(1.Department of Medicine, The Eighth People′s Hospital of Wuxi, Wuxi Jiangsu 214011; 2.Department of Cardiology, Wuxi First Hospital Affiliated to Nanjing Medical University, Wuxi Jiangsu 214023, China)
Abstract：Objective: To explore the values of the serological screening for the ischemia modified albumin(IMA), high-sensitivity C-reactive protein(hs-CRP) and CXC ligand 16(CXCL16) in early acute coronary syndrome (ACS) patients. Methods: A total of 93 patients who were admitted to hospital in 3 hours after chest pain occurred were recruited and divided into control group(n=30) and acute coronary syndrome group(ACS n=63), IMA, hs-CRP and CXCL16 were detected by intravenous haemospasia and compared between the two groups. Results: The levels of serum IMA, hs-CRP and CXCL16 in ACS group were increased significantly compared with the control group(all P<0.01). The results of correlation analysis showed that IMA had a positive correlation with hs-CRP and CXCL16(r=0.286,P<0.05; r=0.301, P<0.05). Conclusion: IMA, hs-CRP and CXCL16 were correlated with ACS, and CXCL16 was probably one of the responsible factors of the high serum IMA and hsCRP levels. They could be the earliest sensitive indicators to the diagnosis and risk estimation of ACS.
收稿日期: 2013-03-20
作者简介: 顾志淼（1972—），女，江苏无锡人，主治医师，主要从事心内科临床诊治的研究。
引用本文:
顾志淼1, 羊镇宇2. 急性冠脉综合征早期血清缺血修饰性白蛋白、高敏C反应蛋白及CXC趋化因子配体16水平检测的意义[J]. 江苏大学学报:医学版, 2013, 23(4): 317-319.
GU Zhi-miao1, YANG Zhen-yu2. Changes and clinical significance of ischemia modified albumin, high-sensitivity C-reactive protein and CXC ligand 16 in early acute coronary syndrome patients. Journal of Jiangsu University(Medicine Edition), 2013, 23(4): 317-319.
［1］Park HE, Cho GY, Chun EJ, et al.Can C-reactive protein predict cardiovascular events in asymptomatic patients? Analysis based on plaque characterization［J］. Atherosclerosis, 2012,224(1):201-207.［2］Corrado E, Rizzo M, Coppola G, et al. An update on the role of markers of inflammation in atherosclerosis ［J］. J Atheroscler Thromb,2010,17(1):1-11.［3］DominguezRodriguez A, Abreu Gonzalez P. Ischemia-modified albumin: we are ready for use in the emergency room［J］. Int J Cardiol,2011,151(2):247.［4］杨长卫,李向荣,邓永盛,等.C反应蛋白与急性冠脉综合症［J］.心血管病学进展,2007, 26(5):781-785.［5］Choi EY, Yan RT, Fernandes VR, et al. High-sensitivity C-reactive protein as an independent predictor of progressive myocardial functional deterioration: the multiethnic study of atherosclerosis［J］. Am Heart J,2012,164(2):251-258.［6］Chandrasekar B, Bysani S, Mummidi S. CXCL16 signals via Gi, phosphatidylinositol 3-kinase, Akt, I kappa B kinase, and nuclear factor-kappa B and induces cellcell adhesion and aortic smooth muscle cell proliferation［J］.J Biol Chem,2004,279(5):3188-3196.［7］Yi GW, Zeng QT, Mao XB, et al. Overexpression of CXCL16 promotes a vulnerable plaque phenotype in Apolipoprotein E-Knockout Mice［J］. Cytokine,2011, 53(3):320-326.［8］张欣,何汝敏,曹久妹. 缺血修饰白蛋白与心肌缺血［J］.国际心血管病杂志,2007,4(4):236-239.［9］罗丹,谢曙光. 缺血修饰白蛋白、肌红蛋白和肌钙蛋白联合检测诊断早期急性心肌梗死［J］.江西医学检验,2006,24(4):299-301.［10］Abadie JM, Blassingame CL, Bankson DD. Albumin cobalt binding assay to rule out acute coronary syndrome［J］.Ann Clin Lab Sci,2005,35(1):66-72.［11］Sinha MK, Roy D, Gaze DC, et al. Role of “Ischemia Modified Albumin”,a new biochemical marker of myocardial ischaemia,in the early diagnosis of acute coronary syndromes［J］.Emerg Med J,2004,21(1):29-34.［12］Garrido IP, Roy D, Calvino R, et al. Comparison of ischemia-modified albumin levels in patients undergoing percutaneous coronary intervention for unstable angina pectoris with versus without coronary collaterals［J］.Am J Cardiol,2004,93(1):88-90.［13］丁士芳,张运,张梅,等. 斑块稳定性与炎症反应在急性冠状动脉综合症中作用的研究［J］.中华心血管病杂志,2006,34(6):512-514.［14］Aslanian AM, Charo IF. Targeted disruption of the scavenger receptor and chemokine CXCL16 accelerates atherosclerosis［J］. Circulation,2006,114(6):583-590.［15］Wuttge DM, Zhou X, Sheikine Y,et al. CXCL16／SRPSOX is an interferon-gamma-regulated chemokine and scavenger receptor expressed in atherosclerotic lesions［J］. Arterioscler Thromb Vasc Biol,2004,24(4):750-755.
2013, Vol. 23 
